• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by IDEAYA Biosciences Inc.

    8/5/25 4:19:07 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IDYA alert in real time by email
    S-8 1 idya-20250805.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on August 5, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    IDEAYA Biosciences, Inc.

    (Exact name of Registrant as specified in its charter)

    Delaware

    47-4268251

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    5000 Shoreline Court, Suite 300

    94080

    South San Francisco, California

    (Address of Principal Executive Offices)

    (Zip Code)

     

    IDEAYA Biosciences, Inc. 2023 Employment

    Inducement Award Plan

    (Full Title of the Plan)

    Yujiro Hata

    President and Chief Executive Officer

    IDEAYA Biosciences, Inc.

    5000 Shoreline Court, Suite 300

    South San Francisco, California 94080

    (650) 443-6209

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Mark V. Roeder, Esq.

    John C. Williams, Esq.

    Latham & Watkins LLP

    140 Scott Drive

    Menlo Park, California 94025

    (650) 328-4600

     


     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☒

    Accelerated filer

    ☐

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☐

     

     

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”).

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    In this Registration Statement, IDEAYA Biosciences, Inc. is sometimes referred to as “Registrant.”

     

    REGISTRATION OF ADDITIONAL SECURITIES

    PURSUANT TO GENERAL INSTRUCTION E OF FORM S-8

    This Registration Statement on Form S-8 (the “Registration Statement”) is being filed with the Commission for the purpose of registering an additional 2,000,000 shares of common stock, par value $0.0001 per share (“common stock”) of the Registrant issuable under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Award Plan, as amended (the “Inducement Plan”) pursuant to which the Registrant had previously reserved 2,000,000 shares of common stock. Shares available for issuance under the Inducement Plan were previously registered on registration statements on Form S-8 filed with the Commission on March 7, 2023 (File No. 333-270334) and August 6, 2024 (File No. 333-281301) (collectively, the “Prior Registration Statements”). The Prior Registration Statements are currently effective. This Registration Statement relates to securities of the same class as those for which the Prior Registration Statements relate. The Inducement Plan was adopted and amended by the Registrant’s board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market. Pursuant to Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated by reference herein to the extent not modified or superseded hereby or by any subsequently filed document, which is incorporated by reference herein, except for Item 8, which is being updated by this Registration Statement.

    Item 3. Incorporation of Documents by Reference.

    The following documents previously filed by the Registrant with the Commission are incorporated by reference in this Registration Statement:

    (a)

    the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Commission on February 18, 2025;

     

     

     

     

    (b)

    the Registrant’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025 and June 30, 2025, filed with the Commission on May 6, 2025 and August 5, 2025, respectively;

     

     

     

     

    (c)

    the Registrant’s Current Reports on Form 8-K filed with the Commission on February 10, 2025, April 2, 2025, June 24, 2025 and June 27, 2025;

    (d)

    the information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K from the Registrant’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 30, 2025; and

    (e)

    the description of the Registrant’s common stock contained in the Registrant’s “Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934” filed as Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024 and any amendments or reports filed for the purpose of updating such description.

    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to the registration statement which indicates that all of the

     


     

    shares of common stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, that is not deemed filed under such provisions. For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Under no circumstances will any information filed under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

     

    Item 8. Exhibits.

     

    Exhibit

    Incorporated by Reference

    Filed Herewith

    Number

    Exhibit Description

    Form

    Date

    Number

     

    4.1

    Amended and Restated Certificate of Incorporation.

    8-K

    5-28-19

    3.1

     

     

    4.2

    Amended and Restated Bylaws.

    8-K

    5-28-19

    3.2

     

     

    4.3

    Form of Common Stock Certificate.

    S-1/A

       5-13-19

    4.2

     

     

    5.1

    Opinion of Latham & Watkins LLP.

     

     

     

     

     

     

    X

    23.1

    Consent of Independent Registered Public Accounting Firm.

     

     

     

     

     

     

    X

    23.2

    Consent of Latham & Watkins LLP (included in Exhibit 5.1).

     

     

     

     

     

     

    X

    24.1

    Power of Attorney (included on signature page).

     

     

     

     

     

     

    X

    99.1(a)#

    2023 Employment Inducement Award Plan.

     

    S-8

    3-7-2023

     

    99.3(a)

     

    99.1(b)#

    Form of Stock Option Grant Notice and Stock Option Agreement under the 2023 Employment Inducement Award Plan.

     

    S-8

    3-7-2023

     

    99.3(b)

     

    99.1(c)#

    Amendment, effective as of June 25, 2024, to the 2023 Employment Inducement Award Plan.

     

    S-8

    8-6-2024

     

    99.1(c)

     

    99.1(d)#

    Amendment, effective as of May 21, 2025, to the 2023 Employment Inducement Award Plan.

     

    10-Q

    8-5-2025

     

    10.3

     

    107.1

    Filing Fee Table.

     

     

     

     

     

     

    X

     

    #

    Indicates management contract or compensatory plan.

     

     


     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California, on this 5th day of August, 2025.

    IDEAYA Biosciences, Inc.

     

     

    By:

    /s/ Yujiro Hata

     

    Yujiro Hata

     

    President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Yujiro Hata and Joshua Bleharski, Ph.D., and each of them acting individually, as his true and lawful attorneys-in-fact and agents, each with full power of substitution, for him in any and all capacities, to sign any and all amendments to this Registration Statement, including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    Signature

    Title

    Date

    /s/ Yujiro Hata

    Yujiro Hata

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

    August 5, 2025

    /s/ Joshua Bleharski, Ph.D.

    Joshua Bleharski, Ph.D.

    Chief Financial Officer

    (Principal Financial Officer)

    August 5, 2025

    /s/ Terry Rosen, Ph.D.

    Terry Rosen, Ph.D.

    Chairman of the Board of Directors

    August 5, 2025

    /s/ Garret Hampton, Ph.D.

    Garret Hampton, Ph.D.

    Director

    August 5, 2025

    /s/ Catherine Mackey, Ph.D.

    Catherine Mackey, Ph.D.

    Director

    August 5, 2025

    /s/ Scott Morrison

    Scott Morrison

    Director

    August 5, 2025

    /s/ Jeffrey Stein, Ph.D.

    Director

    August 5, 2025

    Jeffrey Stein, Ph.D.

     

     

    /s/ Wendy Yarno

    Wendy Yarno

    Director

          August 5, 2025

     

     


    Get the next $IDYA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IDYA

    DatePrice TargetRatingAnalyst
    9/4/2025$40.00Overweight
    Barclays
    9/4/2025$41.00Mkt Outperform
    Citizens JMP
    7/22/2025Buy
    TD Cowen
    7/10/2025$25.00Neutral
    Goldman
    6/26/2025$44.00Overweight
    Wells Fargo
    11/18/2024$51.00Overweight
    Stephens
    11/5/2024$27.00Outperform → Market Perform
    Leerink Partners
    10/24/2024$50.00Buy
    UBS
    More analyst ratings

    $IDYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Bleharski Joshua

    3 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

    6/27/25 4:20:15 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Yarno Wendy L

    4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

    6/26/25 4:57:37 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Stein Jeffrey

    4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

    6/26/25 4:56:47 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on IDEAYA Biosciences with a new price target

    Barclays initiated coverage of IDEAYA Biosciences with a rating of Overweight and set a new price target of $40.00

    9/4/25 9:01:02 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens JMP initiated coverage on IDEAYA Biosciences with a new price target

    Citizens JMP initiated coverage of IDEAYA Biosciences with a rating of Mkt Outperform and set a new price target of $41.00

    9/4/25 9:00:51 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on IDEAYA Biosciences

    TD Cowen initiated coverage of IDEAYA Biosciences with a rating of Buy

    7/22/25 7:52:34 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    SEC Filings

    View All

    SEC Form 8-K filed by IDEAYA Biosciences Inc.

    8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)

    9/8/25 6:08:13 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by IDEAYA Biosciences Inc.

    8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)

    9/2/25 6:02:27 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by IDEAYA Biosciences Inc.

    SCHEDULE 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

    8/14/25 11:33:09 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 8, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development timelines for life-saving cancer treatments[1], while major pharmaceutical companies deployed several multi-billion-dollar strategic partnerhips (with one topping $11 billion) to secure next-generation immunotherapies[2]. These recent designations are creating momentum for companies advancing breakthrough oncology platforms including Oncolytics Biotech Inc. (NASDAQ:ONCY), HUTCHMED (China) Limited (NASDAQ:HCM), CG Oncology, Inc. (NASDAQ

    9/8/25 9:30:00 AM ET
    $CCCC
    $CGON
    $HCM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer

    Overall response rate (ORR) of 57% (4/7; 3cPR+1uPR) in patients treated with a combination of 30 mg IDE397 plus 7.5mg/kg Trodelvy® (Dose level 2); ORR of 33% (3/9; 3cPR) at 15 mg IDE397 plus 10mg/kg Trodelvy® (Dose level 1)Manageable safety profile at both expansion doses, consistent with known adverse events observed with each agent alone, with no treatment related serious adverse events observed at the IDE397 30mg and Trodelvy® 7.5 mg/kg expansion doseSelection of recommended Phase 2 dose is targeted by end of 2025, with next update planned for a medical conference in H1 2026  SOUTH SAN FRANCISCO, Calif., Sept. 8, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading preci

    9/8/25 8:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma

    Treatment with darovasertib resulted in robust ocular tumor shrinkage, lower simulated radiation doses to the eye and meaningful visual gains and reduced long-term risk of blindness for patients in the neoadjuvant setting of primary uveal melanomaManageable safety profile with mostly Grade 1 and 2 treatment-related adverse eventsPhase 3 registration-enabling OptimUM-10 trial of darovasertib in neoadjuvant primary UM initiated during the second quarter of 2025SOUTH SAN FRANCISCO, Calif., Sept. 8, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, will present positive interim data at their 10-Year Anniversary R&D Day from their ongoing

    9/8/25 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    Leadership Updates

    Live Leadership Updates

    View All

    IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Joshua Bleharski, Ph.D. as Chief Financial Officer.  Dr. Bleharski joins IDEAYA from J.P. Morgan, where he spent nearly 17 years advising clients in the biopharma sector on capital markets transactions, corporate strategy and other investment banking services. IDEAYA anticipates that Dr. Bleharski will complete the transition into his new role by early May. 

    2/10/25 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

    Brings over 20-year global commercialization experience in oncology with leading biopharmaceutical companies Gilead Sciences and Bristol Myers Squibb, including leadership of multiple commercial launches for products including Trodelvy® and Opdivo®SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Stu Dorman as Chief Commercial Officer. Mr. Dorman has a track record of commercial success in numerous specialty disease areas with over 20 years of oncology and hematology experience.

    11/18/24 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

    Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm

    9/18/24 6:00:00 AM ET
    $IDYA
    $GWPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    $IDYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

    SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

    11/14/24 4:23:02 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

    SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

    11/14/24 3:13:37 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

    SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

    11/14/24 1:22:38 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    Financials

    Live finance-specific insights

    View All

    IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

    Phase 2 company-sponsored and IST neoadjuvant uveal melanoma (UM) clinical data update in 49 evaluable patients, demonstrates ~49% of patients with >30% tumor shrinkage by product of diameters, and ~61% eye preservation rate for enucleation patientsTargeting to initiate Phase 3 randomized registrational trial in neoadjuvant UM following finalization of the clinical protocol with FDAClinical endpoints supportive of full approval based on FDA guidance: Eye preservation rate as the primary endpoint for enucleation patients. Time to vision loss as the primary endpoint for plaque brachytherapy patients. No detriment to Event-Free-Survival (EFS) in the treatment arms is a secondary endpointDiscuss

    9/23/24 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

    SOUTH SAN FRANCISCO, Calif., Sept. 22, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the company plans to issue a pre-market press release and conduct an investor webcast on Monday, September 23, 2024, at 8:00 a.m. ET to report interim Phase 2 data for darovasertib and provide a regulatory update from FDA Type C meeting in neoadjuvant uveal melanoma (UM). Darovasertib is a potent and selective protein kinase C (PKC) inhibitor being developed to broadly address primary and metastatic UM.

    9/22/24 9:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer

    ~39% Overall Response Rate (ORR): 1 CR and 6 PRs (2 awaiting confirmation) by RECIST 1.1 out of 18 evaluable MTAP-deletion urothelial and NSCLC patients~94% Disease Control Rate (DCR): 1 CR and 6 PRs and 10 SD by RECIST 1.1~78% of Patients with Tumor Shrinkage: 14 patients observed tumor shrinkage~81% ctDNA Molecular Response Rate (MRR): 13 of 16 patients with > 50% ctDNA reductionAE Profile: ~5.6% drug-related grade >3 AEs and no drug-related SAEs or discontinuations at 30 mg once-a-day expansion doseIDE397 expansion dose of 30 mg once-a-day achieved target drug coverage and plasma SAM pharmacodynamic reduction associated with preclinical tumor regressions~48k U.S. annual incidence of MTAP-

    7/8/24 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care